New genome-editing technology to help treat blood cancers

March 13, 2015, Walter and Eliza Hall Institute
Australian researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.Dr Brandon Aubrey, Dr Gemma Kelly and Dr Marco Herold (L-R) from the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, led the research.Using the technology they were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival. Credit: Walter and Eliza Hall Institute of Medical Research.

Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.

Using the technology, researchers from the Walter and Eliza Hall Institute were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.

The research, published in the journal Cell Reports, provides a 'proof of concept' for using the technology as a direct treatment for human diseases arising from genetic 'errors'.

Dr Brandon Aubrey, Dr Gemma Kelly and Dr Marco Herold adapted the technology, called CRISPR, to specifically mimic and study blood cancers. The Walter and Eliza Hall Institute has one of the most advanced CRISPR laboratories in Australia, established and led by Dr Herold.

Dr Aubrey, who is also a haematologist at The Royal Melbourne Hospital, said the team used the CRISPR technology to target and directly manipulate genes in blood .

"Using preclinical models, we were able to kill human Burkitt lymphoma cells by deleting MCL-1, a gene that has been shown to keep cancer cells alive," he said. "Our study showed that the CRISPR technology can directly kill cancer cells by targeting factors that are essential for their survival and growth. As a clinician, it is very exciting to see the prospect of new technology that could in the future provide new treatment options for cancer patients."

The CRISPR/Cas9 system works by efficiently locating and targeting particular genes of interest in the whole genome. It can either target the gene to introduce mutations that make the gene non-functional, or introduce changes that make mutated genes function normally again.

Dr Herold said pharmaceutical companies around the world were already investing millions of dollars to develop CRISPR as a tool for treating genetic diseases such as cancer.

"There is a lot of excitement and a significant amount of resources being invested worldwide to use CRISPR technology for treating patients," Dr Herold said. "The technology can directly target any gene in the person's genome, therefore overcoming many common drug development problems.

"In our study, we showed for the first time that it is possible for CRISPR technology to be used in cancer therapy, however CRISPR is a unique approach that could potentially be used for treating any disease that is caused by genetic mutations. The speed at which we are now able to make specific changes in the DNA will also accelerate basic research discoveries in the lab," Dr Herold said.

More than 50 research groups from around Australia have sought Dr Herold's expertise and are working with the laboratory to adapt the technology for their own research.

Dr Herold said CRISPR was a very new technology with many advantages over existing tools. "CRISPR is a rapid, easy and efficient technology with the best results for genome editing," he said.

"In addition to its very exciting potential for disease treatment, we have shown that it has the potential to identify novel mutations in cancer-causing genes and genes that 'suppress' cancer development, which will help us to identify how they initiate or accelerate the development of cancer.

"The technology dramatically shortens the time frame for fundamental research, allowing us to speed up the discoveries that could be translated to better diagnostics and treatments for the community."

Explore further: In vivo CRISPR-Cas9 screen sheds light on cancer metastasis and tumor evolution

Related Stories

In vivo CRISPR-Cas9 screen sheds light on cancer metastasis and tumor evolution

March 5, 2015
For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome. A team of scientists at the Broad Institute and MIT's David H. Koch Institute ...

Cellular scissors chop up HIV virus

March 10, 2015
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced ...

Recommended for you

Scientists take step toward new, targeted lung cancer treatment

August 21, 2018
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.

Annual pap test a 'thing of the past?'

August 21, 2018
The United States Preventive Services Task Force (USPSTF) has released new recommendations on screening for cervical cancer. These latest recommendations continue the trend of decreasing participant burden by lengthening ...

'Liquid biopsy' predicts lymphoma therapy success within days, study finds

August 20, 2018
A blood test can predict which patients with a type of cancer called diffuse large B cell lymphoma are likely to respond positively to initial therapy and which are likely to need more aggressive treatment, according to a ...

Study shows how to make (and destroy) a metastatic cancer cell

August 20, 2018
Many cancers become especially dangerous only when they metastasize from their site of origin to faraway tissues such as lung, brain or bone. Now, a University of Colorado Cancer Center study published today in the Proceedings ...

Study details effect of radiation exposure on hormone deficiencies

August 20, 2018
In a new study, University of Cincinnati (UC) researchers, in collaboration with Massachusetts General Hospital, have detailed the effect of radiation exposure on the development of hormone deficiency in pediatric and young ...

Research team develops predictor for immunotherapy response in melanoma

August 20, 2018
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy. ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Shapoval
not rated yet Mar 19, 2015
Father of Oncology discovers Iron-Related Genes involved in Blood Cancers. Although the specific cause of blood cancer is not known, a number of factors are associated with its development, researchers say. Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy. The Father of Oncology says that blood cancer is a form of iron lottery. At the cellular level, blood cancer occurs when cellular iron overload chaotically affects cellular molecules and organelles (DNA, chromosomes, mitochondria, etc). Blood cancer occurs when excessive iron is deposited in the bone marrow or in the lymphatic system. Blood cancer is always caused by iron-related genes (genes directly/indirectly involved in iron metabolism) and iron-related events (when excessive iron accumulates within blood-forming tissue due to various carcinogenic events) http://www.medica...s/183856 ; Medical Xpress & MNT & Vadim Shapoval

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.